Latest / The Vox Markets Podcast
2382: 2026 Could Be a Defining Year for POLB 001 and Oral GLP-1
Poolbeg Pharma CEO Jeremy Skillington discusses progress across POLB 001, including regulatory clearance, IP protection, US payer research and the path towards interim clinical data in cancer immunotherapy-induced CRS. He also updates investors on the company’s cash runway, partnering strategy and the potential commercial opportunity in oral GLP-1 therapies.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.